Joseph L. Turner's most recent trade in Arcutis Biotherapeutics Inc was a trade of 11,796 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 1, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics Inc | Joseph L. Turner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 11,796 | 11,796 | - | - | Stock Option (Right to Buy) | |
| Arcutis Biotherapeutics Inc | Joseph L. Turner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 4,312 | 4,312 (0%) | 0% | 0 | Common Stock | |
| Arcutis Biotherapeutics Inc | Joseph L. Turner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 13,391 | 13,391 | - | - | Stock Option (Right to Buy) | |
| Viridian Therapeutics Inc | Joseph L. Turner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 25,000 | 25,000 | - | - | Director Stock Option (Right to Buy) |